Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235408 | 1.00 | CXCR4 (0.56) | CXCR4APEX1TERTADRB1HTR2A | |
| SCHEMBL29520740 | 1.00 | CXCR4 (0.56) | CXCR4APEX1TERTADRB1HTR2A | |
| SCHEMBL9207672 | 0.97 | CXCR4 (0.58) | CXCR4APEX1TERTADRB1HTR2A | |
| SCHEMBL20837979 | 0.91 | CXCR4 (0.53) | CXCR4APEX1TERTADRB1HTR2A | |
| SCHEMBL29418138 | 0.88 | CXCR4 (0.51) | CXCR4APEX1TERTADRB1HTR2A | |
| SCHEMBL13495066 | 0.87 | CXCR4 (0.52) | CXCR4ADRB1HTR2AHTR3EHTR3B | |
| SCHEMBL31649015 | 0.86 | CXCR4 (0.53) | CXCR4ADRB1HTR2AHTR3EHTR3B | |
| SCHEMBL14206482 | 0.82 | CXCR4 (0.50) | CXCR4APEX1ADRB1HTR2AHTR2C | |
| SCHEMBL8260287 | 0.82 | CXCR4 (0.43) | CXCR4APEX1TERTADRB1HTR2A | |
| SCHEMBL18312432 | 0.81 | CXCR4 (0.49) | CXCR4APEX1HTR2CKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211146-B1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | UNIV BAR ILAN (IL) | 2026-05-20 | — | — | EP | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4444709-B1 | FAP-ALPHA SPECIFIC TUMOR DIAGNOSTIC IMAGING AGENT | JIAXING PHARMADAX GENESIS PHARMACEUTICAL TECH CO LTD (CN) | 2026-02-25 | — | — | EP | claimed |
| US-20250360218-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-11-27 | — | — | US | claimed |
| US-20250325718-A1 | IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES | JANSSEN BIOTECH INC (US) | 2025-10-23 | — | — | US | claimed |
| WO-2025122363-A2 | METHODS OF TREATING SMALL CELL LUNG CANCER | Evergreen Discovery, LLC (US) | 2025-06-12 | — | — | WO | claimed |
| US-20250186634-A1 | METHODS OF TREATING SMALL CELL LUNG CANCER | Evergreen Discovery, LLC (US) | 2025-06-12 | — | — | US | claimed |
| WO-2025111445-A1 | TROP-2 RADIOPHARMACEUTICAL CONJUGATE AND USES THEREOF | CONVERGENT THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250135047-A1 | IMPROVED ALUMINUM FLUORIDE RADIOSYNTHESIS OF [18F]DK222 | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | claimed |
| US-20250101475-A1 | MONOOXYGENASE MUTANTS FOR BIOSYNTHESIS OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE AND A METHOD FOR PREPARATION OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE USING THE SAID MONOOXYGENASE MUTANTS | VIO CHEMICALS AG (CH) | 2025-03-27 | — | — | US | claimed |
| EP-3902800-B1 | COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED FROM A DIASTEREOISOMERICALLY ENRICHED PCTA AND PREPARATION AND PURIFICATION PROCESS | GUERBET SA (FR) | 2022-09-07 | — | — | EP | claimed |
| WO-2022174809-A1 | ANTI-CLDN18.2 ANTIBODY CONJUGATES | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2022-08-25 | — | — | WO | claimed |
| WO-2022162549-A2 | IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| EP-3902799-B1 | COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED OF A DIASTEREOISOMERICALLY ENRICHED PCTA AND SYNTHESIS METHOD | GUERBET SA (FR) | 2022-07-27 | — | — | EP | claimed |
| WO-2022032100-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-10 | — | — | WO | claimed |
| US-20210196840-A1 | GADOLINIUM BEARING PCTA-BASED CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2021-07-01 | — | — | US | claimed |
| EP-3770160-A1 | GADOLINIUM BEARING PCTA-BASED CONTRAST AGENTS | Bracco Imaging SPA (IT) | 2021-01-27 | — | — | EP | claimed |
| EP-0698029-B1 | PROCESS FOR THE PREPARATION OF AZAMACROCYLCIC OR ACYCLIC AMINOPHOSPHONATE ESTER DERIVATIVES | DOW CHEMICAL CO (US) | 1998-11-04 | — | — | EP | claimed |
| EP-0698029-A1 | PROCESS FOR THE PREPARATION OF AZAMACROCYLCIC OR ACYCLIC AMINOPHOSPHONATE ESTER DERIVATIVES | THE DOW CHEMICAL COMPANY (US) | 1996-02-28 | — | — | EP | claimed |
| WO-1994026753-A1 | PROCESS FOR THE PREPARATION OF AZAMACROCYLCIC OR ACYCLIC AMINOPHOSPHONATE ESTER DERIVATIVES | THE DOW CHEMICAL COMPANY (US) | 1994-11-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360218-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | TSPO, TFAM, MCU | CXCR4 2273/4885APEX1 2123/4885TERT 1663/4885 |
| US-20250135047-A1 | IMPROVED ALUMINUM FLUORIDE RADIOSYNTHESIS OF [18F]DK222 | PDCD1LG2, CD274, PDCD1 | CXCR4 684/4885APEX1 510/4885TERT 3718/4885 |
| US-20210196840-A1 | GADOLINIUM BEARING PCTA-BASED CONTRAST AGENTS | GLRA1, GLRA2, GLRX3 | CXCR4 2338/4885APEX1 2587/4885TERT 3400/4885 |
| US-20250186634-A1 | METHODS OF TREATING SMALL CELL LUNG CANCER | SSTR2, CCKBR, GRPR | CXCR4 460/4885APEX1 4480/4885TERT 1050/4885 |
| US-20250325718-A1 | IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES | KLK3, KLK2, KLKB1 | CXCR4 2755/4885APEX1 2478/4885TERT 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.